Announcements
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
- Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
- Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
- Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
- Vericel to Present at the Stephens Annual Investment Conference
- Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
- Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.40 |
---|---|
High | 47.80 |
Low | 47.40 |
Bid | 47.20 |
Offer | 52.00 |
Previous close | 44.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 48.38m |
Free float | 47.98m |
P/E (TTM) | -- |
Market cap | 2.53bn USD |
EPS (TTM) | -0.0684 USD |
Data delayed at least 15 minutes, as of Mar 28 2024.
More ▼